Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Belviq Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

NCT02400359
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Lorcaserin HCl, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 1:35 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin for Preventing Weight Gain Among Smokers

NCT02393547
View directory record Official record
Conditions
Tobacco Use Disorder, Weight Gain
Interventions
Varenicline, Lorcaserin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Lorcaserin, Placebo Oral Capsule
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

NCT03338296
View directory record Official record
Conditions
Obesity
Interventions
lorcaserin hydrochloride XR, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Bell Gardens, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 17, 2026, 1:35 AM EDT
Not listed Phase 4 Interventional

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

NCT01962402
View directory record Official record
Conditions
Weight Gain
Interventions
lorcaserin, Intensive dietary counseling
Drug · Behavioral
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 17, 2026, 1:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT03552107
View directory record Official record
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

NCT00828932
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Results available

Treatment With Lorcaserin for Cocaine Use: The TLC Study

NCT03192995
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
lorcaserin, Placebo Oral Tablet, Substance use counseling, ACASI, Cocaine metabolites, Ecological Momentary Assessment (EMA), Balloon Analogue Risk Task (BART), Qualitative Exit Interview
Drug · Behavioral · Diagnostic Test
Lead sponsor
Glenn-Milo Santos
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Lorcaserin for Smoking Cessation

NCT04396834
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking Cessation
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956
View directory record Official record
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

NCT02388568
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 17, 2026, 1:35 AM EDT
Available No phase listed Expanded access

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

NCT04457687
View directory record Official record
Conditions
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Early Phase 1 Interventional Results available

Lorcaserin for Cannabis Use Disorder

NCT03637842
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Lorcaserin, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

NCT03253926
View directory record Official record
Conditions
Cannabis Use
Interventions
Lorcaserin, Placebo, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Predictors of Lorcaserin-Induced Weight Loss

NCT03353220
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Belviq, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

NCT04396847
View directory record Official record
Conditions
Alcohol Use Disorder, Tobacco Smoking
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874
View directory record Official record
Conditions
Smoking Cessation
Interventions
APD356-lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
31
States / cities
Encino, California • Escondido, California • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Lorcaserin, Placebo, Cocaine Infusion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

NCT02906644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
lorcaserin, nicotine patch, placebo lorcaserin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 17, 2026, 1:35 AM EDT